knowledge -WSS

knowledge

author：Wikipedia 2025-09-28 23:29:55 - browse：971

Janet Woodcock -- health policy coverage from STAT — Janet Woodcock, the FDA's principal deputy commissioner Chip Somodevilla/Getty Images

WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime drug chief, but she’s drawn the battle plans for the agency’s next chapter.

Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of therapies and several clashes with Congress and patient advocates. In recent years, she also warded off attacks on the agency’s decisionmaking during the Covid-19 pandemic, particularly when the agency veteran took the acting commissioner role during President Biden’s long search for a permanent leader, and took charge of a vast reorganization plan sparked by the baby formula crisis.

Some of those efforts still hang in the balance as she departs this week. Critics argue that under her oversight, the drug division worked too closely with pharmaceutical companies to give broad approvals to new medicines like Biogen’s Aduhelm or so-called accelerated approval to controversial therapies like Sarepta’s Duchenne muscular dystrophy medicine Exondys 51, which is still in the midst of post-marketing studies to prove its effectiveness.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Louisiana bill approved classifying abortion pills as controlled substances

WSS

Medical students need to learn the potent medicine of empathy

Hospitals need to get ahead of regulations on climate change

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Too many hospitalized Covid

Protect nursing home residents from future pandemics

Decentralized clinical trials need collaboration to achieve wider use

entertainment

knowledge

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

Beyond aggravation: Constipation is an American epidemic

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Activists slam private health insurers over coverage restrictions

Congress: Prevent baby formula shortages by passing a new bill

Wildfire smoke exposes gaps in outdoor worker protections

Bernie Sanders gets little from pharma CEOs on drug prices

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Eli Lilly reports tirzepatide MASH success during Q4 earnings

leisure time

Bernie Sanders gets little from pharma CEOs on drug prices

The Bio Revolution is changing business and society

Beyond aggravation: Constipation is an American epidemic

Should insurance cover cosmetic surgery?

Abbott's new heart device gets FDA advisory panel nod

Louisiana bill approved classifying abortion pills as controlled substances

hotspot

focus

focus

explore